Migrasome Therapeutics joins Roche Accelerator to speed up migrasome-based drug development

May 12, 2023, Beijing –Beijing Migrasome Therapeutics Ltd. (Migrasome Therapeutics) announced thecompany became a member of the Roche Accelerator. With the support from RocheAccelerator, Migrasome Therapeuctics is developing migrasome-based drugdelivery platform and new therapeutics in Immunology and Oncology.

Drug Delivery System (DDS) involves materialsor devices used to control the release, targeting and absorption in vivo oftherapeutics. New generation of DDS is being developed to offer solutions totarget different cell types, overcome complex biological barriers (includingblood-brain-barrier) or to enhance the delivery efficiency of complextherapeutics (such as nucleic acid therapeutics). Migrasome is a novel organellediscovered and named by Prof. Li Yu, Scientific Founder of MigrasomeTherapeutics, and represents a new biology worldwide. By laveraging the uniquefeatures of migrasome, nature’s highly-efficient delivery system, MigrasomeTherapeutics strives to develope proprietory engineered migrasome (eMigrasome)drug delivery platform with high capacity, biocompatibility, targetingefficiency, low toxicity and high yield from simple production processes.Meanwhile, Migrasome Therapeutics is also disecting diseases and developing newtherapeutics against novel targets using migrasome biology.

‘We are excited to become a member of theRoche Accelerator. It is a recognition of the novel migrasome biology.’ Prof.Li Yu, Scientific Founder and Scientific Advisor for Migrasome Therapeutics,commented on the acceptance from the Roche Accelerator. ‘We hope a productivecollaboration with Roche Accelerator will help to speed up the development ofmigrasome-based therapeutics and fulfill urgent unmet medical needs.’

About Migrasome Therapeutics

Migrasome Therapeutics Ltd. was founded inApril 2022, and is located in the Life Science Park, Changping District,Beijing. It is an innovative biotechnology company focusing on the novelbiologies of migrasomes. Migrasomes, discovered and comprehensivelyinvestigated by Professor Li Yu’s laboratory, are novel organelles mediatingcommunications between cells and play important roles under normal and diseaseconditions. Based on these findings, Migrasome Therapeutics strives to leveragethe unique features of migrasomes to develop novel therapeutics for multipleurgent unmet medical needs.